Axsome v. Aurobindo: Solriamfetol Method Patents Consolidated in New Jersey
Axsome Malta and Axsome Therapeutics sued Aurobindo Pharma over four patents covering methods of administering solriamfetol to lactating women. Filed in January 2024, the case was consolidated within 125 days into a broader multi-case proceeding involving at least eight related actions in the District of New Jersey.
Solriamfetol patent dispute absorbed into sprawling NJ multi-action
Axsome Malta Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:24-cv-00309 in the District of New Jersey on January 18, 2024, asserting infringement of four US patents — US11779554B1, US11771666B1, US11771667B1, and US11793776B1 — all directed at methods of administering solriamfetol to lactating women. The defendant, Aurobindo Pharma Ltd. and its US affiliate, is a generic pharmaceutical manufacturer whose ANDA filing likely triggered the Hatch-Waxman litigation.
On May 22, 2024, the court ordered the case consolidated with seven other related civil actions — including Nos. 23-20354, 23-23255, 24-196, 24-860, 24-3999, 24-4002, and 24-4608 — into a single consolidated proceeding for discovery, case management, and trial. Consolidation is a procedural outcome, not a merits ruling; it means this case did not end but instead continues under a unified docket alongside actions against other generic challengers.
The 125-day timeline from filing to consolidation is consistent with standard Hatch-Waxman case management practice in New Jersey, where multi-defendant ANDA cases are routinely coordinated. The public record does not disclose settlement terms, claim construction positions, or any substantive rulings on infringement or validity, all of which remain to be resolved in the consolidated action.
Filing to Case Consolidated in 125 days
125 days to consolidation — typical for ANDA-related multi-case coordination in NJ District Court
Case consolidated: what the court’s order means for both parties
Consolidation is procedural — not a merits decision
Consolidation under Federal Rule of Civil Procedure 42(a) allows a court to combine related cases sharing common questions of fact or law. Here, eight separate ANDA infringement actions asserting Axsome’s solriamfetol patents were merged into one proceeding. No findings on infringement, validity, or enforceability have been made. The substantive dispute continues under the consolidated docket.
FRCP 42(a) consolidationAxsome retains all four asserted patents in active litigation
Consolidation does not diminish Axsome’s patent position. All four method patents — covering administration of solriamfetol to lactating women — remain actively asserted. Litigating in a consolidated proceeding may offer Axsome efficiency advantages: unified claim construction and shared discovery against multiple generic challengers reduce cost and risk of inconsistent rulings.
Patents remain enforceableAurobindo now faces coordinated multi-defendant proceedings
Aurobindo Pharma is one of several generic defendants consolidated into a single action. While coordination can streamline Aurobindo’s own discovery burden, it also means Axsome benefits from a unified claim construction record. Aurobindo cannot obtain an ANDA approval free of patent risk until invalidity or non-infringement is established or the 30-month stay expires.
30-month stay likely in effectSolriamfetol generic entry remains blocked pending consolidated trial
With eight related actions now consolidated, the litigation landscape for generic solriamfetol products is centralised in New Jersey. Any ruling on claim construction or invalidity will apply across all consolidated defendants. This structure typically extends effective market exclusivity for the innovator and increases litigation cost and risk for all ANDA filers until a final judgment is entered.
Generic entry delayedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical innovator — holder of US11779554B1 and 3 related solriamfetol method patentsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Generic pharmaceutical manufacturer; ANDA applicant for solriamfetol formulationSearch in Eureka ↗ |
| Co-Defendant | Aurobindo Pharma Limited, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | WILLIAM HARE | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | McNeely, Hare & War LLP | Law Firm | Representing Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s consolidation order is a procedural instrument rather than a substantive ruling. The order merges eight separately filed ANDA infringement actions for all purposes — discovery, case management, and trial — subject to further court direction. No findings on patent validity, claim scope, or infringement have been made. The phrasing ‘for all purposes’ suggests a fully unified proceeding rather than limited coordination, which typically means a single claim construction order will bind all defendants.
US11779554B1 — Methods of administering solriamfetol to lactating women
The four asserted patents — US11779554B1, US11771666B1, US11771667B1, and US11793776B1 — all cover methods of administering solriamfetol, a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness, to a specific patient population: lactating women. Their corrected application numbers (US18/176860, US18/148682, US18/176816, US18/176855) suggest recent continuation filings, consistent with a strategy to maintain prosecution activity around the core compound as it enters the ANDA challenge phase.
Population-specific method-of-use patents of this type are strategically significant because they are difficult to design around with a full-label generic product. Competitors cannot simply omit the lactating women indication if the drug’s approved labelling includes it. The breadth of the consolidated assertion — four patents, eight defendants — suggests Axsome views this patent family as a material pillar of its solriamfetol exclusivity strategy and is prepared to litigate it across the full generic challenger set.
Should you run an FTO against US11779554B1 and the solriamfetol method family?
Any company developing, filing an ANDA for, or distributing a solriamfetol product in the United States should assess freedom-to-operate against all four asserted patents and any pending continuations in the same family. The population-specific method claims mean a standard invalidity or non-infringement analysis for the compound alone is insufficient — label language and indication scope must be reviewed carefully.
PatSnap Eureka’s FTO Search Agent can map the full Axsome solriamfetol patent family, identify pending continuation applications, and flag claim language that may capture broad or narrow administration methods. Eureka’s citation and family tree analysis helps R&D and regulatory teams understand whether a proposed generic label carve-out genuinely avoids these method claims before an ANDA is filed.
Run a freedom-to-operate analysis on US11779554B1 to assess your product’s exposure
Run FTO in Eureka →Similar CNS drug ANDA patent cases in New Jersey District Court
Related Hatch-Waxman method-of-use infringement actions in the District of New Jersey involving CNS and sleep disorder drug patents asserted against generic ANDA filers.
What this case signals for the solriamfetol and CNS drug IP landscape
Eight consolidated ANDA actions signal Axsome is pursuing an aggressive multi-front enforcement strategy for its solriamfetol patent portfolio.
Multi-patent, multi-defendant ANDA consolidation raises the stakes for generic filers
When an innovator asserts four method patents against multiple ANDA filers simultaneously, consolidation concentrates risk for generic challengers. A single adverse claim construction ruling can foreclose all defendants at once. Generic entrants into solriamfetol should model the full patent landscape before filing, not just the lead compound patents.
Method-of-use patents on administration to specific populations are a growing exclusivity tool
All four asserted patents claim methods of administering solriamfetol specifically to lactating women — a population-specific use claim. Such claims are increasingly used by branded pharmaceutical companies to extend effective exclusivity beyond compound patent expiry. Competitors and generics should assess whether skinny-label strategies can carve around such claims.
Axsome v Aurobindo — key questions answered
Case 2:24-cv-00309 was not dismissed or decided on the merits. On May 22, 2024, the court ordered it consolidated with seven other related Axsome solriamfetol patent actions into a single unified proceeding. Litigation over the four asserted patents continues under the consolidated docket.
Axsome asserted four US patents: US11779554B1, US11771666B1, US11771667B1, and US11793776B1. All four cover methods of administering solriamfetol to lactating women and carry application numbers suggesting recent continuation prosecution activity.
Consolidation under FRCP 42(a) merges related cases sharing common facts or legal questions into one proceeding. In ANDA litigation it means all consolidated defendants face the same claim construction ruling and share a single discovery schedule. It does not resolve infringement or validity — those issues remain for the consolidated trial.
The court consolidated eight civil actions: Nos. 23-20354, 23-23255, 24-196, 24-309, 24-860, 24-3999, 24-4002, and 24-4608. All relate to Axsome’s solriamfetol patent portfolio and were consolidated for all purposes including discovery and trial.
Not without risk. In Hatch-Waxman cases, the 30-month stay triggered by the patent holder’s timely lawsuit typically prevents FDA final approval of the ANDA during the stay period. Even after stay expiry, launching at-risk before a final judgment exposes Aurobindo to potential damages. The consolidated proceeding must reach a final merits determination for the patent landscape to clear.
PatSnap Eureka searches patents and litigation data to answer instantly.